ADAR1 Capital Management LLC Invests $4.17 Million in Septerna, Inc. $SEPN

Key Points

• ADAR1 Capital Management LLC acquired 720,848 shares of Septerna, Inc., valued at approximately $4.17 million, indicating growing institutional interest in the company.
• Septerna reported a quarterly earnings miss, with an EPS of ($0.56), falling short of the consensus estimate of ($0.05), and revenue significantly lower than expected at $0.12 million.
• Analysts maintain a generally positive outlook, with four rating the stock as a Buy and an average price target of $26.75, despite recent downgrades.

ADAR1 Capital Management LLC purchased a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 720,848 shares of the company's stock, valued at approximately $4,174,000. ADAR1 Capital Management LLC owned about 1.62% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN acquired a new position in Septerna in the fourth quarter worth about $244,000. Invesco Ltd. acquired a new position in Septerna in the fourth quarter worth $278,000. Barclays PLC bought a new stake in Septerna during the fourth quarter valued at $659,000. MetLife Investment Management LLC acquired a new stake in shares of Septerna during the fourth quarter worth $265,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of Septerna in the 4th quarter worth about $25,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $26.00 price objective on shares of Septerna in a research report on Thursday, August 21st. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Septerna in a research report on Friday. Wells Fargo & Company increased their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Finally, Wall Street Zen raised shares of Septerna from a "sell" rating to a "hold" rating in a report on Friday. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Stock Performance

Shares of NASDAQ SEPN traded up $0.31 during trading on Friday, hitting $14.43. The company had a trading volume of 202,291 shares, compared to its average volume of 259,739. Septerna, Inc. has a 52 week low of $4.17 and a 52 week high of $28.99. The business's 50-day moving average is $12.11 and its 200 day moving average is $9.12. The company has a market cap of $643.36 million and a P/E ratio of -1.43.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $22.50 million. On average, research analysts expect that Septerna, Inc. will post -7.11 EPS for the current year.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.